Methaq Hadi lafta | Biotechnology | Best Academic Researcher Award

Published on by Applied Scientist

Best Academic Researcher Award

Methaq Hadi Lafta
Iraqi Ministry of Education, Iraq
Methaq Hadi Lafta
Affiliation Iraqi Ministry of Education
Country Iraq
Scopus ID 57210173431
Documents 17
Citations 266
h-index 7
Subject Area Biotechnology
Event Applied Scientist Awards
ORCID 0000-0002-9978-6829

Methaq Hadi Lafta has contributed to the fields of biotechnology, molecular biology, immunology, bioinformatics, and environmental sciences through a combination of peer-reviewed publications, editorial responsibilities, and international research collaborations.[1] The Best Academic Researcher Award recognizes distinguished scholarly achievements, scientific productivity, and sustained contributions to interdisciplinary research and academic advancement. His academic profile reflects continued engagement in scientific publishing, reviewer activities, and biomedical research dissemination within regional and international scholarly communities.[2]

Abstract

Methaq Hadi Lafta is associated with multidisciplinary research activities involving biotechnology, molecular diagnostics, cancer biology, nanomaterials, genetics, and biomedical sciences. His scholarly record includes publications indexed in international databases and participation in editorial and reviewer roles across scientific journals. The research profile demonstrates an emphasis on translational biomedical research, computational biology applications, and healthcare-related scientific investigations.[3] The academic contributions and publication metrics support consideration for recognition within the framework of the Applied Scientist Awards.[4]

Keywords

Biotechnology, Molecular Biology, Immunology, Bioinformatics, Genetics, Cancer Research, Nanotechnology, Biomedical Sciences, Scientific Publishing, Academic Research

Introduction

Academic recognition awards are intended to acknowledge researchers whose work contributes to scientific advancement, interdisciplinary collaboration, and evidence-based innovation. In biotechnology and biomedical sciences, contemporary research increasingly integrates computational modeling, molecular analysis, and translational applications aimed at improving healthcare and scientific understanding.[3]

Research Profile

Methaq Hadi Lafta encompasses biotechnology, immunology, microbiology, molecular biology, environmental sciences, and bioinformatics. The profile includes publications addressing autoimmune diseases, cancer biology, nanomaterials, recurrent pregnancy loss, heavy metal toxicity, and computational drug design methodologies.[3]

Research Contributions

Methaq Hadi Lafta involve both experimental and theoretical scientific approaches. Several studies focus on biomedical applications of molecular and cellular biology, particularly within cancer pathways, immunological regulation, and extracellular vesicle technologies.[4]

  • Investigation of extracellular vesicles in autoimmune diseases and stem-cell-derived therapeutic systems.
  • Studies involving MXene-based nanomaterials for microbial toxin sensing and food safety applications.

Publications

Selected publications attributed to Methaq Hadi Lafta include peer-reviewed studies and interdisciplinary biomedical investigations indexed in scholarly databases.[1]

  1. The Developing Role of Extracellular Vesicles in Autoimmune Diseases: Special Attention to Mesenchymal Stem Cell-Derived Extracellular Vesicles.
  2. Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches.

Research Impact

Methaq Hadi Lafta is reflected through publication metrics, citation counts, and interdisciplinary research visibility. According to indexed scholarly data, the profile includes 17 documents with 266 citations and an h-index of 7, indicating measurable scholarly engagement and citation activity within biomedical and biotechnology research areas.[1]

Award Suitability

Methaq Hadi Lafta demonstrates characteristics relevant to the Best Academic Researcher Award within the Applied Scientist Awards framework. The profile combines scientific publications, editorial contributions, interdisciplinary investigations, and participation in international academic networks.[4]

The researcher’s work in biotechnology and biomedical sciences aligns with contemporary scientific priorities involving translational medicine, molecular diagnostics, and innovative therapeutic approaches. Citation metrics, publication activity, and peer-review involvement collectively support suitability for academic recognition.

Conclusion

Methaq Hadi Lafta has established an interdisciplinary research profile spanning biotechnology, molecular medicine, bioinformatics, and biomedical sciences. The scholarly record includes peer-reviewed publications, editorial participation, and measurable research impact indicators. These academic contributions provide a basis for recognition within the Best Academic Researcher Award category associated with the Applied Scientist Awards.[2]

References

  1. Lafta, Methaq Hadi., Saif Adnan M. Advances in Engineering and Intelligence Systems (2022). Strategic Review: The CZTS Thin-Film Using Tandem and Multi-Junction Solar Cell.
    https://aeis.bilijipub.com/article_163968.html
  2. Hadi lafta, M., &  Markov, A. Cell Biology International (2021). P53 long noncoding RNA regulatory network in cancer development.
    https://onlinelibrary.wiley.com/doi/10.1002/cbin.11600
  3. Biomedicine & Pharmacotherapy. (2021). The developing role of extracellular vesicles in autoimmune diseases.
    https://www.sciencedirect.com/science/article/abs/pii/S1567576923008548
  4. Lafta, M.H., & Ahmadi, M. (2021). Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature.
    https://link.springer.com/article/10.1186/s12935-021-01836-9

Shuai Li | Biotechnology | Innovative Research Award

Published on by Applied Scientist

Innovative Research Award

Shuai Li
Regeneron Pharmaceuticals, Inc., United States

Shuai Li
Affiliation Regeneron Pharmaceuticals, Inc.
Country United States
Scopus ID 60626088100
Documents 1
Citations 9
h-index 1
Subject Area Biotechnology
Event Applied Scientist Awards
ORCID 0000-0002-1537-3956

Shuai Li has developed a research portfolio spanning biopharmaceutical formulation development, gene therapy analytics, metabolic engineering, and synthetic biology, with research outputs published in peer-reviewed journals and presented at major scientific conferences.[1] The Innovative Research Award recognizes emerging scientific contributions demonstrating originality, interdisciplinary relevance, and measurable research impact within applied scientific and pharmaceutical innovation. His work at REGENERON and prior academic institutions has focused on analytical characterization of adeno-associated virus (AAV) systems, bioprocess optimization, and translational pharmaceutical technologies.[2]

Abstract

Shuai Li is a researcher working in pharmaceutical sciences, biotechnology, and chemical engineering with emphasis on biologics formulation, gene therapy product characterization, and metabolic engineering. His research integrates analytical chemistry, bioprocess optimization, and automation-driven pharmaceutical development methodologies. Current work at Regeneron Pharmaceuticals, Inc. focuses on accelerated stability optimization platforms, adeno-associated virus formulation technologies, and analytical workflows supporting translational biopharmaceutical development.[2] Previous academic contributions include metabolic pathway engineering in engineered Escherichia coli, dynamic metabolic control systems, and supramolecular chemistry investigations.[3]

Keywords

Biopharmaceutical formulation, AAV stability, gene therapy, metabolic engineering, synthetic biology, analytical chemistry, pharmaceutical sciences, biotechnology, automation platforms, protein engineering.

Introduction

The development of advanced therapeutic biologics and gene therapy systems has accelerated the need for robust analytical technologies, scalable manufacturing workflows, and stability-driven formulation design. Contemporary pharmaceutical research increasingly requires interdisciplinary expertise spanning biotechnology, analytical chemistry, and process engineering.[4] Within this scientific context, Shuai Li has contributed to research involving AAV analytical characterization, formulation optimization, and engineered microbial biosynthesis systems aimed at improving pharmaceutical process efficiency and therapeutic development strategies.[5]

His research activities include high-throughput formulation screening, automated analytical platforms, process transfer methodologies, and characterization techniques supporting preclinical and clinical biologic development. The integration of engineering principles with pharmaceutical sciences has positioned his work within broader efforts to improve stability, manufacturability, and translational feasibility in therapeutic product development.[2]

Research Profile

Shuai Li currently serves as Principal Scientist at Regeneron Pharmaceuticals, Inc. in the United States, where his work centers on drug substance and drug product formulation development for biologics and novel therapeutic modalities, including AAV-based systems and antibody therapeutics.[2] His responsibilities include formulation stability studies, analytical method implementation, developability assessment, and technology transfer to manufacturing environments.

Prior academic research at Duke University focused on dynamic metabolic control systems, engineered microbial biosynthesis, and protein engineering methodologies for chemical production pathways. Earlier work at the Institute of Chemistry, Chinese Academy of Sciences, explored supramolecular chirality, chiral self-assembly, and molecular recognition systems.[3]

  • Principal Scientist, REGENERON Pharmaceuticals
  • Ph.D. in Chemical and Biological Engineering from Duke University
  • Research experience in pharmaceutical sciences and synthetic biology
  • Conference session chair at ASGCT scientific meetings
  • Contributor to analytical and formulation technologies for AAV therapeutics

Research Contributions

Shuai Li has contributed to the development of automated high-throughput systems for accelerated AAV stability optimization and analytical workflows supporting therapeutic characterization.[5] His work includes optimization of SEC methods for characterization of genome DNA leakage in adeno-associated virus products and analytical assessment of degradation pathways under stress conditions.[6]

In metabolic engineering research, he investigated dynamic control mechanisms to improve NADPH fluxes and xylitol biosynthesis in engineered microbial systems. These studies contributed to scalable and process-robust production approaches in engineered E. coli systems.[3]

Additional contributions include development of co-formulation methods, automation-assisted analytical workflows, and biochemical characterization methodologies relevant to pharmaceutical manufacturing and translational biotechnology.[2]

Publications

  • Li, S.; Wang, X.; Zhi, L.; Shameem, M.; Liu, D. “A high-throughput automation platform for accelerated AAV stability optimization.” Pharmaceutics, 2026.
  • Li, S.; Wang, X.; et al. “Development of an optimized SEC method for characterization of genome DNA leakage from adeno-associated virus products.” Analytical and Bioanalytical Chemistry, 2024.
  • Li, S.; Ye, Z.; Moreb, E. A.; et al. “2-Stage microfermentations.” Metabolic Engineering Communications, 2024.
  • Sun, Y.; Li, S.; et al. “Alanine-Based Chiral Metallogels via Supramolecular Coordination Complex Platforms.” Journal of the American Chemical Society, 2018.

Research Impact

Shuai Li reflect interdisciplinary integration between pharmaceutical development, analytical chemistry, and metabolic engineering. His scientific contributions have supported analytical characterization strategies for gene therapy systems, including AAV stability and degradation profiling.[5] The combination of automation-driven formulation platforms and scalable bioprocess methodologies demonstrates relevance to modern translational pharmaceutical research environments.

Bibliometric indicators associated with the profile include citations, peer-reviewed publications, conference presentations, and patent filings connected to therapeutic formulation and engineered biosynthesis technologies.[1] Participation as session chair and reviewer within scientific conferences further reflects engagement with the broader biotechnology and pharmaceutical research community.[2]

Award Suitability

Shuai Li demonstrates suitability for recognition within the Innovative Research Award category through contributions spanning biopharmaceutical formulation science, AAV characterization technologies, metabolic engineering, and analytical platform development.[4] His work combines translational applicability with interdisciplinary scientific methodologies relevant to pharmaceutical development and biotechnology innovation.

The profile further reflects active participation in scientific dissemination through peer-reviewed publications, conference leadership activities, patent filings, and collaborative research contributions. The integration of automation, analytical science, and therapeutic product development supports the broader objectives associated with applied scientific innovation awards.[2]

Conclusion

Shuai Li has established a multidisciplinary research profile integrating pharmaceutical sciences, analytical chemistry, biotechnology, and metabolic engineering. His work contributes to the development of advanced analytical methods, formulation technologies, and scalable therapeutic development systems relevant to contemporary biologics and gene therapy research. Through academic publications, patents, scientific leadership activities, and translational research efforts, the profile demonstrates alignment with the objectives of the Innovative Research Award and the Applied Scientist Awards program.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Shuai Li, Author ID 60626088100. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=60626088100
  2. Li, S. (2026). Professional Curriculum Vitae and Research Profile. REGENERON Pharmaceuticals.
    https://scholar.google.com/citations?user=gGjwsxkAAAAJ&hl=en
  3. Li, S.; Ye, Z.; Moreb, E. A.; et al. (2021). Dynamic control over feedback regulatory mechanisms improves NADPH fluxes and xylitol biosynthesis in engineered E. coli. Metabolic Engineering, 64, 26-40.
    https://doi.org/10.1016/j.ymben.2020.12.002
  4. Li Zhang, Han-Xiao Wang, Shuai Li, Minghua Liu. Supramolecular chiroptical switches.
    https://pubs.rsc.org/en/content/articlehtml/2020/cs/d0cs00191k
  5. Li, S,. et al. HardwareX (2021). BioSamplr: An open source, low cost automated sampling system for bioreactors. Pharmaceutics, 18(5), 608.
    https://www.sciencedirect.com/science/article/pii/S2468067221000067
  6. Chen, Y.; Li, S.; Li, S.; et al. (2023). Lyophilization as an effective tool to develop AAV8 gene therapy products for refrigerated storage
    https://www.sciencedirect.com/science/article/pii/S0378517323009857

Njayou Frederic Nico | Drug Discovery | Best Researcher Award

Published on by Applied Scientist

Prof. Njayou Frederic Nico | Drug Discovery | Best Researcher Award

Researcher |University of Yaounde 1 | Cameroon

Prof. Njayou Frederic Nico, is a Full Professor of Biochemistry, Pharmacology, and Toxicology at the University of Yaounde I, where he has built an outstanding career in scientific research, teaching, and community development. His expertise spans the study and valorization of medicinal plants and wild mushrooms for the treatment of inflammatory, parasitic, viral, bacterial, and neurological diseases, including hepatitis, gastric ulcer, malaria, Alzheimer’s, and Parkinson’s disease. He has made significant contributions through in vitro and in vivo studies using chemistry, molecular biology, enzymology, and biochemistry tools, leading to the discovery of several plant and mushroom species with strong therapeutic potential. A Fulbright Visiting Scholar at the University of Connecticut (2012–2013), he gained advanced training in cell culture, western blotting, and PCR, which enhanced his capacity to conduct high-quality research. He has supervised numerous Master’s and PhD theses, published widely, and contributed to innovation, including the development of improved traditional medicines and cosmetics. Beyond academia, he is engaged in training communities on sustainable harvesting and health awareness. His scientific output includes 311 citations from 35 indexed documents with an h-index of 11, underscoring his impact in pharmacology and biochemistry research.

Profile : Scopus | ORCID

Featured Publications

  • Magoudjou Pekam, J. N., Efange, N. M., Mishro, L., Keumoe, R., Ndjakou, B. L., Ayong, L., Njayou, F. N., Moundipa, P. F., & Rajendran, V. (2025). In vitro antiplasmodial activities of extracts and fractions from Lepidobotrys staudtii against sensitive and resistant blood-stage parasites of Plasmodium falciparum. International Journal for Parasitology: Drugs and Drug Resistance.

  • Fils Armand Ella, A., Dupon Akamba Ambamba, B., Njayou, F. N., & Moundipa, P. F. (2025). Khaya grandifolia exerts multitarget neuroprotective potential against neurodegenerative disorders: In vitro and in silico studies. IBRO Neuroscience Reports, 19, 400–408.

  • Tchana, J. C. T., Ayissi Owona, B., Messi, N. A., Kouam Kamgue, T. N., Sebdou, A., Ngoungoure Ndam, V., Kouamo, M. M. F., Njayou, F. N., & Moundipa, P. F. (2025). Effects of Garcinia Manni Oliv. biflavonoids on a model of aluminum chloride (AlCl3)-induced Alzheimer’s disease in Drosophila. International Journal of Biochemistry Research & Review, 34(4), 369–388.

  • Deussom, P. M., Ewonkem, M. B., Enang, B., Kamdem, M. H. K., Mbock, M. A., Fotsing, M. C. D., Ndinteh, D. T., Njayou, F. N., & Toze, F. A. (2025). Synthesis and biological evaluation of esterified anti-inflammatory drugs with ethylene glycol linkers: Cytotoxicity, anti-inflammatory and antioxidant properties. Royal Society Open Science, 12, 241413.

  • Ngohoba, V. S., Pechangou, N. S., Njayou, F. N., & Moundipa, P. F. (2025). Therapeutic targets associated with medical research in the treatment of inflammatory bowel disease. medtigo JPharmacol, 1(1), e14202205.